Selank: The Nootropic Anxiety-Relief Peptide — Complete Guide (2026)

Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. While compounds like BPC-157 and TB-500 dominate conversations around physical recovery, and GLP-1 agonists reshape metabolic medicine, Selank carved out a niche at the intersection of anxiety relief, cognitive enhancement, and immune modulation.

Approved in Russia since 2009 for generalized anxiety disorder (GAD) and neurasthenia, Selank has accumulated a meaningful body of peer-reviewed evidence. Its profile — anxiolytic without dependence, nootropic without stimulation, immunomodulatory without immunosuppression — makes it one of the more clinically interesting peptides available for research.

What Is Selank?

Selank (TKPRPGP) is a synthetic analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of the IgG immunoglobulin heavy chain. Russian researchers created Selank by appending the stabilizing tripeptide Pro-Gly-Pro to the native tuftsin sequence — creating a compound with substantially greater metabolic stability, prolonged biological activity, and an expanded mechanism profile.

Selank's presence in human pineal gland extract was confirmed in 2017, establishing its endogenous relevance. Its molecular weight is approximately 751 Da.

Mechanism of Action

GABAergic Modulation

The primary anxiolytic mechanism involves the GABA-A receptor complex. Selank modulates GABAergic neurotransmission producing anxiety relief comparable to low-dose benzodiazepines — but without sedation, tolerance, physical dependence, or withdrawal. A published head-to-head clinical trial comparing Selank to medazepam in 62 patients with GAD found equivalent anxiety reduction, with Selank additionally showing antiasthenic effects and mild psychostimulation absent in the benzodiazepine group.

BDNF Upregulation

Research by Inozemtseva et al. demonstrated that Selank rapidly boosts brain-derived neurotrophic factor (BDNF) mRNA expression in the rat hippocampus within hours of administration. BDNF is central to neuroplasticity, neuroprotection, and memory consolidation — the mechanistic basis for Selank's cognitive-enhancing properties.

In models of ethanol-induced pathological BDNF elevation, Selank normalized BDNF levels while improving cognitive performance — demonstrating context-sensitive neurotrophic modulation rather than simple upregulation.

Enkephalin Metabolism

Selank inhibits aminopeptidase N (APN) and dipeptidyl peptidase IV (DPP-IV), the key enzymes responsible for enkephalin degradation. By slowing the breakdown of endogenous opioid peptides, Selank prolongs their natural calming effects without directly activating opioid receptors — a critical safety distinction.

Monoaminergic Effects

Rodent studies show increased 5-HIAA to serotonin ratios in the hypothalamus and striatum, indicating accelerated serotonin turnover. Dopamine metabolism shifts in parallel — consistent with the mild alertness and mood-uplifting quality users report without agitation or jitteriness.

Clinical Research Evidence

Anxiety and Neurasthenia

The landmark controlled trial (Seredenin et al., 2008) enrolled 62 patients with GAD and neurasthenia, randomized to Selank or medazepam. Results showed equivalent anxiolytic efficacy with Selank demonstrating additional antiasthenic and psychostimulant effects. Multiple open-label cohorts confirmed reductions in Hamilton Anxiety Scale (HAM-A) scores comparable to benzodiazepine treatment, without adverse effects on psychomotor function or memory.

Cognitive Performance

BDNF upregulation data provides a mechanistic basis for cognitive effects. In anxiety-impaired learning models, Selank restored task performance to control levels — suggesting improvements are partly mediated by anxiety reduction and partly by direct neurotrophic signaling.

Immune Modulation

PubMed-indexed studies on immunomodulatory effects in patients found Selank normalized immune function parameters in subjects with altered baseline immune status — consistent with its tuftsin heritage. Selank appears to modulate rather than suppress or stimulate immunity.

Selank vs. Semax: Key Differences

Selank and Semax are frequently compared as the two flagship Russian nootropic/anxiolytic peptides:

• Primary profile: Selank = anxiolytic with mild cognitive enhancement; Semax = nootropic with cognitive acceleration
• Mechanism: Selank targets GABAergic pathways; Semax primarily acts via BDNF and dopaminergic modulation
• Stimulation: Selank is calming; Semax has a moderate stimulant quality
• Route: Both are typically administered intranasally or subcutaneously

A popular research combination stacks both together: Semax provides cognitive drive while Selank prevents overstimulation and anxiety — thought to enhance learning-intensive protocols.

Dosing and Administration

Selank is most commonly administered intranasally in research contexts, achieving peak CSF concentrations within approximately 30 minutes. Subcutaneous injection is also documented.

Standard Research Dosing

• Intranasal: 100–500 mcg per dose, 1–3 times daily
• Subcutaneous: 250–500 mcg per injection, 1–2 times daily
• Starting dose: 100–200 mcg to assess individual response
• Optimal clinical dose: 300 mcg/kg in rodent studies; human trials used 150–300 mcg per administration

Cycle Length

Russian clinical protocols typically use 10–14 day courses, repeatable. Unlike benzodiazepines, no tolerance or dependence profile has been reported — making longer or cyclical use more feasible from a safety standpoint.

Intranasal Preparation

Reconstituted Selank for intranasal use is typically prepared at 0.15% (1.5 mg/mL). Each nasal spray pump delivers approximately 100 mcg depending on calibration.

Safety Profile

• Low acute toxicity confirmed in animal studies at multiples of therapeutic doses
• No tolerance or dependence — the defining safety advantage over benzodiazepines
• No sedation or psychomotor impairment — subjects maintained normal cognitive and motor function in trials
• No significant adverse effects in chronic administration studies
• Minor local effects: mild nasal irritation or transient taste/odor changes with intranasal use
• No abuse potential identified in preclinical dependency models

Regulatory Status

Selank has been approved and registered in Russia as a pharmaceutical treatment for GAD and neurasthenia under the brand name Selanc since 2009. It is not FDA- or EMA-approved and is classified as a research compound outside Russia and CIS countries.

Conclusion

Selank occupies a genuinely distinctive position in the peptide landscape — an effective anxiolytic with a clean safety profile, a mild cognitive enhancer, and an immunomodulator with a plausible endogenous mechanism. The clinical track record in Russia is real, the pharmacology is well-characterized, and the absence of benzodiazepine-like side effects is not a theoretical advantage but a demonstrated one.

For researchers and clinicians exploring peptide-based approaches to anxiety and cognitive performance, Selank is one of the more evidence-grounded compounds available.

Note: Selank is a research compound. This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before considering any peptide protocol.